Nkarta (NKTX) News Today → America could fall from this event (From Porter & Company) (Ad) Free NKTX Stock Alerts $6.55 -0.03 (-0.46%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 3:34 PM | marketbeat.comNeedham & Company LLC Cuts Nkarta (NASDAQ:NKTX) Price Target to $13.00Needham & Company LLC dropped their price objective on shares of Nkarta from $15.00 to $13.00 and set a "buy" rating for the company in a report on Monday.May 13 at 3:33 PM | marketbeat.comNkarta (NASDAQ:NKTX) Price Target Increased to $23.00 by Analysts at HC WainwrightHC Wainwright raised their price objective on shares of Nkarta from $22.00 to $23.00 and gave the stock a "buy" rating in a report on Monday.May 12 at 4:58 AM | americanbankingnews.comNkarta (NASDAQ:NKTX) PT Lowered to $15.00May 10, 2024 | finance.yahoo.comNkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational AnalysisMay 10, 2024 | finanznachrichten.deNkarta, Inc.: Nkarta Reports First Quarter 2024 Financial Results and Corporate HighlightsMay 10, 2024 | markets.businessinsider.comNkarta Inc. Buy Rating Affirmed Amidst Promising Clinical Studies and Robust Financial HealthMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed: Nkarta’s NKX019 Shows Promise in Lupus Nephritis Clinical TrialsMay 10, 2024 | investorplace.comNKTX Stock Earnings: Nkarta Beats EPS for Q1 2024May 9, 2024 | finance.yahoo.comNkarta Reports First Quarter 2024 Financial Results and Corporate HighlightsMay 9, 2024 | globenewswire.comNkarta Reports First Quarter 2024 Financial Results and Corporate HighlightsMay 7, 2024 | investorplace.comOpportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street's RadarApril 27, 2024 | msn.comAmgen’s Blincyto data send Cullinan higherApril 27, 2024 | seekingalpha.comNkarta: Down 50% Since March With A Clinical Catalyst AheadApril 18, 2024 | finance.yahoo.comNkarta, Inc. (NKTX) Interactive Stock Chart - Yahoo FinanceApril 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)April 10, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Arcutis Biotherapeutics (ARQT)April 10, 2024 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for Nkarta (NASDAQ:NKTX)Needham & Company LLC reissued a "buy" rating and set a $15.00 price objective on shares of Nkarta in a report on Wednesday.April 8, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsApril 5, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsApril 5, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsApril 3, 2024 | globenewswire.comNkarta to Participate in Upcoming Investor ConferencesApril 2, 2024 | marketbeat.comNkarta (NASDAQ:NKTX) Stock Price Down 5.7%Nkarta (NASDAQ:NKTX) Stock Price Down 5.7%April 1, 2024 | marketbeat.comNkarta (NASDAQ:NKTX) Shares Gap Up to $10.81Nkarta (NASDAQ:NKTX) Shares Gap Up to $10.81March 31, 2024 | 247wallst.comHuge Insider Buying From Buffett, an NFL Team Owner, a New CEOMarch 30, 2024 | insidertrades.comSimeon George Purchases 2,000,000 Shares of Nkarta, Inc. (NASDAQ:NKTX) StockMarch 28, 2024 | marketbeat.comNkarta, Inc. (NASDAQ:NKTX) Director Acquires $20,000,000.00 in StockNkarta, Inc. (NASDAQ:NKTX - Get Free Report) Director Simeon George bought 2,000,000 shares of the business's stock in a transaction on Wednesday, March 27th. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $20,000,000.00. Following the completion of the purchase, the director now owns 1,548,341 shares in the company, valued at $15,483,410. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.March 27, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)March 27, 2024 | msn.comPromising Biopharma Nkarta (NASDAQ:NKTX) Not For the Faint-HeartedMarch 26, 2024 | marketbeat.comNkarta (NASDAQ:NKTX) Price Target Increased to $16.00 by Analysts at Canaccord Genuity GroupCanaccord Genuity Group increased their price target on shares of Nkarta from $15.00 to $16.00 and gave the company a "buy" rating in a research report on Tuesday.March 26, 2024 | sg.finance.yahoo.comNkarta, Inc. (NKTX) interactive stock chart – Yahoo FinanceMarch 25, 2024 | seekingalpha.comNkarta: NK Cell Therapy Advancement On Two FrontsMarch 25, 2024 | msn.comNkarta announces pricing of stock offering to raise $240.1MMarch 25, 2024 | markets.businessinsider.comNkarta Prices $240 Mln Offering; Stock Up Over 16%March 25, 2024 | globenewswire.comNkarta Announces Pricing of $240 Million Underwritten OfferingMarch 25, 2024 | markets.businessinsider.comNkarta’s Strategic Pivot to CAR-NK Therapies for Autoimmune Diseases Prompts Buy RatingMarch 23, 2024 | finance.yahoo.comNkarta Inc (NKTX) Posts Full Year 2023 Financial Results: A Focus on NKX019 and Pipeline RealignmentMarch 22, 2024 | finanznachrichten.deNkarta, Inc.: Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsMarch 22, 2024 | markets.businessinsider.comBuy Rating for Nkarta: Promising Future for NKX019 in Autoimmune Disease TreatmentMarch 22, 2024 | markets.businessinsider.comNkarta’s Strategic Focus and Financial Strength Underpin Buy RatingMarch 22, 2024 | msn.comThese Analysts Revise Their Forecasts On Nkarta After Q4 ResultsMarch 22, 2024 | marketbeat.comNkarta (NASDAQ:NKTX) Given New $25.00 Price Target at MizuhoMizuho dropped their price target on Nkarta from $31.00 to $25.00 and set a "buy" rating on the stock in a research note on Friday.March 22, 2024 | marketbeat.comTrading was temporarily halted for "NKTX" at 09:03 AM with a stated reason of "LULD pause."March 22, 2024 | marketbeat.comNkarta (NASDAQ:NKTX) Receives Outperform Rating from Raymond JamesRaymond James reaffirmed an "outperform" rating and issued a $16.00 price target (up previously from $13.00) on shares of Nkarta in a research note on Friday.March 21, 2024 | investorplace.comNKTX Stock Earnings: Nkarta Beats EPS for Q4 2023March 21, 2024 | globenewswire.comNkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsMarch 19, 2024 | marketbeat.comNkarta (NASDAQ:NKTX) Stock Price Up 8.4%Nkarta (NASDAQ:NKTX) Trading Up 8.4%March 19, 2024 | markets.businessinsider.comInnovative NK-Cell Therapy: A Buy Rating for Nkarta’s Groundbreaking Approach to Autoimmune DiseasesMarch 19, 2024 | investorplace.com3 Overlooked Stocks Ready to Capture the Market by StormMarch 18, 2024 | finance.yahoo.comNKTX Apr 2024 30.000 callMarch 16, 2024 | finance.yahoo.comNKTX Apr 2024 17.500 put Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address America could fall from this event (Ad)America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash. Click here to see how you can protect yourself today. NKTX Media Mentions By Week NKTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKTX News Sentiment▼0.100.57▲Average Medical News Sentiment NKTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKTX Articles This Week▼162▲NKTX Articles Average Week Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Atea Pharmaceuticals News Today Atai Life Sciences News Today Precigen News Today Ventyx Biosciences News Today Verrica Pharmaceuticals News Today Kamada News Today Organogenesis News Today CorMedix News Today Neoleukin Therapeutics News Today Vanda Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NKTX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressElon to Transform U.S. Economy? Porter & CompanyThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
